Article info
PDFOriginal research
Unethical informed consent caused by overlooking poorly measured nocebo effects
- Correspondence to Dr Jeremy Howick, Faculty of Philosophy, University of Oxford, Oxford OX2 6GG, UK; jeremy.howick{at}philosophy.ox.ac.uk
Citation
Unethical informed consent caused by overlooking poorly measured nocebo effects
Publication history
- Received October 23, 2019
- Revised January 4, 2020
- Accepted January 13, 2020
- First published February 16, 2020.
Online issue publication
August 23, 2021
Article Versions
- Previous version (16 February 2020).
- Previous version (19 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
- Impact of patient information leaflets on doctor – patient communication in the context of acute conditions: a prospective, controlled, before – after study in two French emergency departments
- Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
- The nocebo effect: patient expectations and medication side effects
- Assessing the quality of written information provision for surgical procedures: a case study in oesophagectomy
- Readability and understandability of clinical research patient information leaflets and consent forms in Ireland and the UK: a retrospective quantitative analysis
- Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Open - label placebo clinical trials: is it the rationale, the interaction or the pill
- Unhelpful information about adverse drug reactions